Lori A Hazlehurst , PhD

Professor

Organization:

West Virginia University School of Pharmacy

Department:

Pharmaceutical Sciences

Classification:

Faculty

Associate Director of Basic Research

Organization:

West Virginia University WVU Cancer Institute

Department:

WVU Cancer Institute Administration

Classification:

Faculty

Co-Leader Alexander B. Osborn Hematopoietic Malignancy and Transplantation

Organization:

West Virginia University WVU Cancer Institute

Department:

WVU Cancer Institute Research Programs

Classification:

Faculty

The Mitochondrial mitoNEET Ligand NL-1 Is Protective in a Murine Model of Transient Cerebral Ischemic Stroke.
Saralkar P, Mdzinarishvili A, Arsiwala TA, Lee YK, Sullivan PG, Pinti MV, Hollander JM, Kelley EE, Ren X, Hu H, Simpkins J, Brown C, Hazlehurst LE, Huber JD and Geldenhuys WJ.
Pharm Res. 2021.

Role of Calcium Homeostasis in Modulating EMT in Cancer.
Jones CA and Hazlehurst LA.
Biomedicines. 2021;9(9).

Bioactivity improvement via display of the hydrophobic core of HYD1 in a cyclic ß-hairpin-like scaffold, MTI-101.
Jain P, Badger DB, Liang Y, Gebhard AW, Santiago D, Murray P, Kaulagari SR, Gauthier TJ, Nair R, Kumar M, Guida WC, Hazlehurst LA and McLaughlin ML.
Peptide Science. 2021;113(3).

Transient Receptor Potential C 1/4/5 Is a Determinant of MTI-101 Induced Calcium Influx and Cell Death in Multiple Myeloma.
Elzamzamy OM, Johnson BE, Chen WC, Hu G, Penner R and Hazlehurst LA.
Cells. 2021;10(6).

The Role of TRPC1 in Modulating Cancer Progression.
Elzamzamy OM, Penner R and Hazlehurst LA.
Cells. 2020;9(2).

Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors.
Chen WC, Hu G and Hazlehurst LA.
Curr Opin Pharmacol. 2020;54:36-43.

A Virtual Screening Platform Identifies Chloroethylagelastatin A as a Potential Ribosomal Inhibitor.
Caulfield TR, Hayes KE, Qiu Y, Coban M, Seok Oh J, Lane AL, Yoshimitsu T, Hazlehurst L, Copland JA and Tun HW.
Biomolecules. 2020;10(10).

Hypoxia-induced PIM kinase and laminin-activated integrin alpha6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC.
Toth RK, Tran JD, Muldong MT, Nollet EA, Schulz VV, Jensen CC, Hazlehurst LA, Corey E, Durden D, Jamieson C, Miranti CK and Warfel NA.
Am J Clin Exp Urol. 2019;7(4):297-312.

Inhibition of the FAD containing ER oxidoreductin 1 (Ero1) protein by EN-460 as a strategy for treatment of multiple myeloma.
Hayes KE, Batsomboon P, Chen WC, Johnson BD, Becker A, Eschrich SA, Yang Y, Robart AR, Dudley GB, Geldenhuys WJ and Hazlehurst LA.
Bioorg Med Chem. 2019;27(8):1479-1488.

Inhibition of the FAD containing ER oxidoreductin 1 (Ero1) protein by EN-460 as a strategy for treatment of multiple myeloma.
Hayes KE, Batsomboon P, Chen WC, Johnson BD, Becker A, Eschrich S, Yang Y, Robart AR, Dudley GB, Geldenhuys WJ and Hazlehurst LA.
Bioorganic and Medicinal Chemistry. 2019;27(8):1479-1488.

Crystal structure of the mitochondrial protein mitoNEET bound to a benze-sulfonide ligand.
Geldenhuys WJ, Long TE, Saralkar PA, Iwasaki T, Nunez RAA, Nair RR, Konkle ME, Menze MA, Pinti MV, Hollander JM, Hazlehurst LA and Robart AR.
Communications Chemistry. 2019;2.

Fellowships

1997-1999  NIH NSRA post-doctoral fellowship, “Isolation of A Selected Drug Resistant Gene”

2000-2001 Multiple Myeloma Research Foundation junior fellowship, “The role of CDK2 in fibronectin induced regulation of p27 levels

Presentations

2011 Educational Session: Emerging Opportunities for Targeting CAM-DR AACR. Orlando, FL

2014 Invited for oral presentation at SBIR investor forum for November 11^th , Santa Clara California

2015 Invited platform presentation at the NCI investor forum southeast region, Durham, NC

Patents

Peptides for the treatment of cancer

Integrin interaction inhibitors for the treatment of cancer.

Peptides for treatment of bone deficiency and autoimmunce disorders

Materials and methods for treating oncological disorders

HYD1 Peptides as Anti-Cancer Agents

Education:

Post-doctoral Training- University of Arizona and the Moffitt Cancer Center

Graduate Training - Ph.D., Cell and Molecular Biology University of Vermont, 1994

Dr. Hazlehurst earned her Ph.D. from the Cell and Molecular Biology Program at the University of Vermont. Her post-doctoral studies were performed at the University of Arizona and the Moffitt Cancer Center.  Her studies focused on developing strategies for targeting the tumor microenvironment to increase the efficacy of standard of care agents.  Her current research focus is to develop strategies for targeting Ca²⁺ homeostasis in cancer.  The laboratory focus is translational with an overall goal of developing novel therapeutic strategies for the treatment of cancer.

Positions:

1999- 2001 Research Assistant Professor, University of South Florida, College of Medicine Department of Interdisciplinary Oncology

2001- 2002 Research Assistant Professor, University of Arizona

2002- 2007 Assistant Professor, University of South Florida, College of Medicine, Department of Interdisciplinary Oncology

2008-2015 Associate Member Moffitt Cancer Center

2011-Present Modulation Therapeutics Co-Founder

Alexander B. Osborn Hematopoietic Malignancy and Transplantation Co-Leader

Dr. Lori Hazlehurst has a strong background in experimental therapeutics. Her research interests are focused on discovering novel therapeutic strategies for the treatment of hematological malignances.  To this end herlaboratory is currently investigating the potential of targeting i) integrin mediated pathways  ii) the unfolded protein response and iii) identification of novel targets that are appreciated in the context of tumor cell bone marrow microenvironment interactions. She and her research partner propose that the first selection pressure is the tumor microenvironment and second pressure is drug selection.  Identification of vulnerabilities that occur during the evolution of tumor progression in this context will enable discovery of new targets for the treatment of drug-resistant cancer.

Her overarching goal is to identify druggable targets and upon validation our laboratory utilizes both HTS strategies and collaborative efforts with chemistry colleagues to define lead compounds that can be utilized to better understand cancer biology and if warranted move towards translational development.  She is also co-founder of Modulation Therapeutics which is focused on bridging the valley of death of lead compounds to enable translation to the clinical arena.

R21 CA191981   Specific skeletal targeting of MMP-2 for the treatment of multiple myeloma

1R01CA195727-01 Targeting CD44-mediated calcium signaling for the treatment of relapsed myeloma